Centre for Endocrine and Diabetes Sciences, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, United Kingdom.
J Clin Endocrinol Metab. 2010 Feb;95(2):722-30. doi: 10.1210/jc.2009-1985. Epub 2009 Dec 8.
Patients with polycystic ovary syndrome (PCOS) have an increased prevalence of insulin resistance and display subclinical evidence of early cardiovascular disease. Metformin improves insulin sensitivity and circulating markers of cardiovascular risk in patients with PCOS, but it is unclear whether this translates into improvements in vascular function.
Our objective was to evaluate the effects of metformin on arterial stiffness and endothelial function in women with PCOS.
Thirty women with PCOS were assigned to consecutive 12-wk treatment periods of metformin or placebo in a randomized, double-blind, crossover design separated by an 8-wk washout.
The primary outcome measures were assessments of arterial stiffness [augmentation index (AIx), central blood pressure, and brachial and aortic pulse wave velocity (PWV)] and endothelial function. Anthropometry, testosterone, and metabolic biochemistry (lipids, homeostasis model of assessment for insulin resistance, high-sensitivity C-reactive protein, adiponectin, and plasminogen activator inhibitor-1) were also assessed.
Metformin improved AIx [-6.1%; 95% confidence interval (CI) for the difference -8.5 to -3.5%; P < 0.001], aortic PWV (-0.76 m/sec; 95% CI for the difference -1.12 to -0.4 m/sec; P < 0.001), brachial PWV (-0.73 m/sec; 95% CI for the difference -1.09 to -0.38; P < 0.001), central blood pressure (P < 0.001), and endothelium-dependent (AIx after albuterol; P = 0.003) and endothelium-independent (AIx after nitroglycerin; P < 0.001) vascular responses. Metformin also reduced weight (P < 0.001), waist circumference (P < 0.001), and triglycerides (P = 0.004) and increased adiponectin (P = 0.001) but did not affect testosterone or other metabolic measures.
Short-term metformin therapy improves arterial stiffness and endothelial function in young women with PCOS.
多囊卵巢综合征(PCOS)患者胰岛素抵抗的发生率增加,并表现出心血管疾病早期的亚临床证据。二甲双胍可改善 PCOS 患者的胰岛素敏感性和循环心血管风险标志物,但尚不清楚这是否转化为血管功能的改善。
我们的目的是评估二甲双胍对 PCOS 女性动脉僵硬度和内皮功能的影响。
30 名 PCOS 女性被随机分配到二甲双胍或安慰剂的 12 周连续治疗期,采用双盲、交叉设计,并在 8 周洗脱期后进行。
主要观察指标为评估动脉僵硬度[增强指数(AIx)、中心血压和肱动脉及主动脉脉搏波速度(PWV)]和内皮功能。还评估了人体测量学、睾酮和代谢生化(血脂、胰岛素抵抗评估的稳态模型、高敏 C 反应蛋白、脂联素和纤溶酶原激活物抑制剂-1)。
二甲双胍改善 AIx[-6.1%;差值的 95%置信区间(CI)为-8.5 至-3.5%;P<0.001]、主动脉 PWV(-0.76 m/sec;差值的 95%CI 为-1.12 至-0.4 m/sec;P<0.001)、肱动脉 PWV(-0.73 m/sec;差值的 95%CI 为-1.09 至-0.38;P<0.001)、中心血压(P<0.001)以及内皮依赖性(沙丁胺醇后 AIx;P=0.003)和内皮非依赖性(硝酸甘油后 AIx;P<0.001)血管反应。二甲双胍还降低了体重(P<0.001)、腰围(P<0.001)和甘油三酯(P=0.004),并增加了脂联素(P=0.001),但对睾酮或其他代谢指标没有影响。
短期二甲双胍治疗可改善年轻 PCOS 女性的动脉僵硬度和内皮功能。